Valneva (VALN) has released an update.
Valneva SE has achieved a significant breakthrough with the European Commission’s approval of IXCHIQ®, the first chikungunya vaccine, for use in adults over 18. This follows prior approvals in the U.S. and Canada, with European distribution expected to commence in late 2024. The vaccine’s availability marks a critical step in combating the spread of the chikungunya virus, which is anticipated to pose a growing threat due to climate-related changes affecting mosquito populations.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
